SYRS News and Press, Syros Pharmaceuticals Inc. From 01/07/21

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the virtual 39 th Annual J.P. Morgan Healthcare Conference...

Syros Pharmaceuticals doubled its stock price in 2020. Syros recently acquired SY-2101 from Orsenix. The main value is still in SY-1425 for AML or MDS. For further details see: Syros Pharmaceuticals After The Orsenix Deal

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, announced today that it has closed a previously announced private financing with a group of institutional accredited investors led by Bain Capital Life Sciences, with part...

Syros Pharmaceuticals (SYRS) acquires from Orsenix all of its assets related to SY-2101, formerly known as ORH-2014, an oral form of arsenic trioxide that's a candidate for treating acute promyelocytic leukemia.Syros has made an upfront cash payment of $12M; Orsenix may be eligible to receive...

Oral Arsenic Trioxide has Potential to Reduce Treatment Burden of Standard-of-Care Regimen that Cures Most Patients Dose Confirmation Study Expected to Begin in Second Half of 2021, Followed by Registration-Enabling Phase 3 Trial in 2022 $90.5 Million Strategic Financi...

61% Composite CR Rate in RARA-Positive Newly Diagnosed Unfit AML Patients, with Median Overall Survival of 18 Months Among Responders Plan to Initiate Registration-Enabling Phase 3 Trial of SY-1425 in Combination with Azacitidine in Newly Diagnosed Higher-Risk MDS in 1Q 2021 ...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a pre-recorded fireside chat as part of the Piper Sandler 32 nd Annual Virt...

Syros Pharmaceuticals, Inc. (SYRS) Q3 2020 Earnings Conference Call November 05, 2020 6:00 AM ET Company Participants Naomi Aoki – Vice President of Corporate Communications and Investor Relations Nancy Simonian – Chief Executive Officer David Roth – Chief Medical Officer...

Presented Initial Clinical Data from Phase 1 Study of SY-5609 at EORTC-NCI-AACR Conference New Clinical and Translational Data for SY-1425 to be Presented at ASH Meeting Management to Host Conference Call at 4:30 p.m. ET Today Syros Pharmaceuticals (NASDAQ:SY...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new clinical data from its fully enrolled, ongoing Phase 2 trial of SY-1425, its first-in-class oral selective retinoic acid receptor ...